TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Google Secures Pentagon AI Deal for Classified Projects 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
WALTHAM, Mass., April 25, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Leerink Boston Biopharma Bus Tour on Wednesday, May 10, 2017. Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, EVP and CFO of TESARO, will present at 1:00 PM ET and will answer questions from investors.
- The Bank of America Merrill Lynch 2017 Healthcare Conference at the Loews Hotel in Las Vegas, Nevada on Wednesday, May 17, 2017. Tim Pearson will participate in an analyst-led moderated Q&A at 3:00 PM PT and in meetings with investors.
A live webcast of the presentation at the Bank of America conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
